ORENCIA injections and infusions for psoriatic arthritis (PsA)

Although rheumatoid arthritis (RA) and psoriatic arthritis (PsA) have some similarities, they are different in several ways. Unlike RA, most people with PsA have psoriasis. This means people can have skin rashes on their body in addition to the joint pain that’s common in arthritis.

Other psoriatic arthritis symptoms include:

  • Joint pain, stiffness, and swelling
  • Nail disease
  • Swollen fingers and toes

Skin symptoms can occur before any joint symptoms start, making it easy to mistake the condition for psoriasis.

ORENCIA was proven to reduce the symptoms of PsA—with or without methotrexate

This clinical study showed that in adults, ORENCIA intravenous (IV) infusion taken with or without methotrexate improved results compared with a placebo IV taken with or without methotrexate. There were 40 people in the ORENCIA group and 42 in the placebo group.

After 6 months of treatment

Reduced symptoms
48% of people felt symptom improvement after taking ORENCIA with or without methotrexate compared with 19% of people taking placebo with or without methotrexate.

Improved physical function
45% of people saw an improvement in physical function after taking ORENCIA with or without methotrexate compared with 19% of people taking placebo with or without methotrexate.

What was the purpose of this study?

This study looked at the results and safety of ORENCIA IV taken with or without methotrexate compared with placebo IV taken with or without methotrexate after 6 months in people who weren't helped enough by the treatments they had taken, like disease-modifying antirheumatic drugs (DMARDs).

Characteristics that people needed to have in order to be included in this study:

  • At least 18 years old
  • Diagnosed with PsA for at least 3 months
  • Living with active PsA
  • Treated with and not helped enough by a DMARD
  • At least one psoriatic skin lesion

What was compared in this study?

The 82 people in this study were randomly placed into 2 groups to help compare their responses to treatment. One group of 40 people received ORENCIA with or without methotrexate, and the other group of 42 people received placebo with or without methotrexate. Their responses were measured by looking at improvements in tender and swollen joint counts (American College of Rheumatology 20% improvement criteria [ACR20]) after 6 months of treatment.

In children and adolescents, other side effects may include:

  • Diarrhea
  • Cough
  • Fever
  • Abdominal pain

This clinical study showed that in adults, ORENCIA self-injection taken with or without methotrexate improved results compared with a placebo self-injection taken with or without methotrexate. There were 213 people in the ORENCIA group and 211 in the placebo group.

After 6 months of treatment

Reduced symptoms
39% of people felt symptom relief after taking ORENCIA with or without methotrexate compared with 22% of people taking placebo with or without methotrexate.

Improved physical function
31% of people saw an improvement in physical function after taking ORENCIA with or without methotrexate compared with 24% of people taking placebo with or without methotrexate.

What was the purpose of this study?

This study looked at the results and safety of ORENCIA self-injection taken with or without methotrexate compared with placebo self-injection taken with or without methotrexate after 6 months in people who weren't helped enough by the disease-modifying antirheumatic drugs (DMARDs) they had previously taken (such as Enbrel® [etanercept] or Humira® [adalimumab]).

Characteristics that people needed to have in order to be included in this study:

  • At least 18 years old
  • Living with active PsA
  • Treated with and not helped enough by a disease-modifying antirheumatic drug (DMARD)
  • At least one psoriatic skin lesion

What was compared in this study?

The 424 people in this study were randomly placed into 2 groups to help compare their responses to treatment. One group of 213 people received ORENCIA with or without methotrexate, and the other group of 211 people received placebo with or without methotrexate. Their responses were measured by looking at improvements in symptoms (ACR20) and how well they could perform daily activities, such as dressing and walking (Health Assessment Questionnaire—Disablity Index).

In children and adolescents, other side effects may include:

  • Diarrhea
  • Cough
  • Fever
  • Abdominal pain